A Phase 3 interventional study of Placebo and Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy and Primary Autonomic Failure, sponsored by Chelsea Therapeutics. Completed at 54 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-20.
Sponsored by Chelsea Therapeutics (part of H. Lundbeck A/S) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing droxidopa in Hypotension, Orthostatic — 2 open to participants now, 2 under way, none of them phase 3. Droxidopa · Hypotension, Orthostatic.
Among the 15 studies testing droxidopa in Hypotension, Orthostatic, this one is the 3rd largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2008, is one of 5 in phase 3, and was the 3rd registered.
159 studies on the registry are indexed under Hypotension, Orthostatic; 35 are open to participants now.
Browse Hypotension, Orthostatic studies →2 of the 15 studies testing droxidopa in Hypotension, Orthostatic are open now, in 1 country. Recruiting first, the newest first:
Stephen G. Kaler · Sites in United States
Ages 7–17
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Droxidopa: first FDA approval 2014 (NORTHERA). What it is approved for, and how studies give it, is on its page →
Of the 23 Hypotension, Orthostatic studies recruiting now, 8 (35%) set no upper age limit and 8 (35%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 1999; this study’s year is marked. 3 started in 2008.
This study's enrollment of 181 is above the median of 28 across 113 interventional studies indexed under Hypotension, Orthostatic.
Median enrollment 28 across the 14 interventional studies. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 15 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chelsea Therapeutics, one of the names counted as H. Lundbeck A/S. Under that name alone:
Chelsea Therapeutics is the lead sponsor of 16 studies on the registry; none are open to participants now.
H. Lundbeck A/S has 6 studies filed under Hypotension, Orthostatic — fewer than ten, so there is no comparison to draw.
1 of the studies testing droxidopa in Hypotension, Orthostatic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01370512Mayo ClinicDroxidopa / Pyridostigmine in Orthostatic Hypotension | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing droxidopa in Hypotension, Orthostatic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see whether droxidopa is effective in treating symptoms of neurogenic orthostatic hypotension in patients with Primary Autonomic Failure (Pure Autonomic Failure, Multiple System Atrophy, Parkinson's Disease), Non-diabetic neuropathy, or Beta Hydroxylase deficiency.
Systolic blood pressure is transiently and minimally decreased in healthy individuals upon standing. Normal physiologic feedback mechanisms work through neurally-mediated pathways to maintain the standing blood pressure, and thus maintain adequate cerebral perfusion. The compensatory mechanisms that regulate blood pressure upon standing are dysfunctional in subjects with orthostatic hypotension (OH), a condition that may lead to inadequate cerebral perfusion with accompanying symptoms of syncope, dizziness or lightheadedness, unsteadiness and blurred or impaired vision, among other symptoms.
The autonomic nervous system has a central role in the regulation of blood pressure. Primary Autonomic Failure is manifested in a variety of syndromes. Orthostatic hypotension is a usual presenting symptom. Primary Autonomic Failure may be the primary diagnosis, and classifications include pure autonomic failure (PAF), also called idiopathic orthostatic hypotension (Bradbury-Eggleston syndrome) autonomic failure with multiple system atrophy (Shy-Drager syndrome) and also Parkinson's disease. Regardless of the primary condition, autonomic dysfunction underlies orthostatic hypotension.
Orthostatic hypotension may be a severely disabling condition which can seriously interfere with the quality of life of afflicted subjects. Currently available therapeutic options provide some symptomatic relief in a subset of subjects, but are relatively ineffective and are often accompanied by severe side effects that limit their usefulness. Support garments (tight-fitting leotard) may prove useful in some subjects, but is difficult to don without family or nursing assistance, especially for older subjects. Midodrine, fludrocortisone, methylphenidate, ephedrine, indomethacin and dihydroergotamine are among some of the pharmacological interventions that have been used to treat orthostatic hypotension, although only midodrine is specifically approved for this indication. The limitations of these currently available therapeutic options, and the incapacitating nature and often progressive downhill course of disease, point to the need for an improved therapeutic alternative.
The current withdrawal design study will measure the efficacy of droxidopa on symptoms of neurogenic orthostatic hypotension in patients randomized to continued droxidopa treatment versus placebo, following 14 days of double-blind treatment.
droxidopa
droxidopa [also, known as L-threo-3,4-dihydroxyphenylserine, L-threo-DOPS, or L-DOPS] is the International non-proprietary name (INN) for a synthetic amino acid precursor of norepinephrine (NE), which was originally developed by Sumitomo Pharmaceuticals Co., Limited, Japan. It has been approved for use in Japan since 1989. Droxidopa has been shown to improve symptoms of orthostatic hypotension that result from a variety of conditions including Shy Drager syndrome (Multiple System Atrophy), Pure Autonomic Failure, and Parkinson's disease. There are four stereoisomers of DOPS; however, only the L-threo-enantiomer (droxidopa) is biologically active.
The exact mechanism of action of droxidopa in the treatment of symptomatic NOH has not been precisely defined; however, its NE replenishing properties with concomitant recovery of decreased noradrenergic activity are considered to be of major importance.
Droxidopa has been marketed in Japan since 1989. Data from clinical studies and post-marketing surveillance programs conducted in Japan show that the most commonly reported adverse drug reactions with droxidopa are increased blood pressure, nausea, and headache. In clinical studies, the prevalence and severity of droxidopa adverse effects appear to be similar to those reported by the placebo control arm.
PATIENT INCLUSION CRITERIA:
MAIN PATIENT EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-blind
Drug: Droxidopa
Double-blind
Drug: Placebo
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Also known as: L-DOPS, L-threo-DOPS, Northera
Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)
OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Fatigue (OHSA Item 4)
OHSA item 4 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Weakness (OHSA Item 3)
OHSA item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Vision (OHSA Item 2)
OHSA item 2 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Concentration (OHSA Item 5)
OHSA item 5 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Head/Neck Discomfort (OHSA Item 6)
OHSA item 6 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score)
The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite)
The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6)
OHSA composite scale (items 2-6) is the average of five OHSA items: 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing;
Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
Time frame: 14 days
| Milestone | Open Label Titration | Droxidopa | Placebo |
|---|---|---|---|
| Started | 181 | 0 | 0 |
| Completed | 101 | 0 | 0 |
| Not completed | 80 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 |
| Withdrew: Adverse event | 13 | 0 | 0 |
| Withdrew: Treatment failure | 55 | 0 | 0 |
| Withdrew: Protocol violation | 6 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 |
| Milestone | Open Label Titration | Droxidopa | Placebo |
|---|---|---|---|
| Started | 0 | 50 | 51 |
| Completed | 0 | 50 | 51 |
| Not completed | 0 | 0 | 0 |
OHSA item 1 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1) | 1.3 ± 2.75 | 1.9 ± 3.16 |
OHSA item 4 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Fatigue (OHSA Item 4) | 0.7 ± 2.61 | 1.5 ± 2.72 |
OHSA item 3 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Weakness (OHSA Item 3) | 0.3 ± 2.88 | 1.2 ± 2.70 |
OHSA item 2 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Vision (OHSA Item 2) | 1.1 ± 2.79 | 0.8 ± 2.24 |
OHSA item 5 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Concentration (OHSA Item 5) | 0.1 ± 2.74 | 0.9 ± 2.67 |
The OHQ is the average of two sub-scales, the Orthostatic Hypotension Symptom Assessment Scale (OHSA) and the Orthostatic Hypotension Daily Activities Scale (OHDAS). Each asks the patient to rate their symptoms or disease impact over the past week. The OHSA sub-scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. The OHDAS sub-scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Orthostatic Hypotension Questionnaire Score (OHQ) | 0.11 ± 2.176 | 1.22 ± 2.390 |
OHSA item 6 scale range: 0 (none) -10 (worst), likert scale. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Head/Neck Discomfort (OHSA Item 6) | -0.1 ± 2.45 | 1.2 ± 3.19 |
The OHDAS scale is the average of four items: 1) Standing for a short time; 2) Standing for a long time; 3) Walking for a short time; and 4) Walking for a long time. Each asks the patient to rate their disease impact over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Ability to Conduct Activities of Daily Living Score (OHDAS Composite Score) | -0.24 ± 2.35 | 0.91 ± 2.50 |
The OHSA scale is the average of six items: 1) Dizziness, lightheadedness, feeling faint or feeling like you might black out; 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Orthostatic Hypotension Symptom Assessment Score (OHSA Composite) | 0.6 ± 2.27 | 1.35 ± 2.53 |
OHSA composite scale (items 2-6) is the average of five OHSA items: 2) Problems with vision; 3) Weakness; 4) Fatigue; 5) Trouble concentrating; and 6) Head/neck discomfort. Each asks the patient to rate their symptoms over the past week. Each item is scored on a Likert scale from 0 to 10, with 10 being the most severe. Change: score at end of study minus score at randomization. In this withdrawal design, a positive score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| units on a scale | Droxidopa | Placebo |
|---|---|---|
| Change in Orthostatic Hypotension Symptom Scores Excluding Dizziness (OHSA Composite Items 2-6) | 0.44 ± 2.29 | 1.07 ± 2.25 |
Change: standing systolic blood pressure at end of study minus standing systolic blood pressure at randomization. In this withdrawal design, a negative score indicates worsening during the double-blind randomized phase relative to value at randomization (on open-label drug) .
| mmHg | Droxidopa | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure (SBP) Measurements 3 Minutes Post Standing; | -7.6 ± 19.71 | -5.2 ± 26.83 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Droxidopa | — | 0/50 (0%) | 4/50 (8%) |
| Placebo | — | 1/51 (2%) | 11/51 (21.6%) |
| Open Label Phase | — | 4/181 (2.2%) | 44/181 (24.3%) |
| Event | Droxidopa | Placebo | Open Label Phase |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/50 | 1/51 | 0/181 |
| Mental status changePsychiatric disorders | 0/50 | 1/51 | 0/181 |
| Coronary artery diseaseCardiac disorders | 0/50 | 0/51 | 1/181 |
| Cardiac failure congestiveCardiac disorders | 0/50 | 0/51 | 1/181 |
| PneumoniaInfections and infestations | 0/50 | 0/51 | 1/181 |
| leukopeniaBlood and lymphatic system disorders | 0/50 | 0/51 | 1/181 |
| Orthostatic hypotensionVascular disorders | 0/50 | 0/51 | 1/181 |
| Event | Droxidopa | Placebo | Open Label Phase |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 1/50 | 6/51 | 9/181 |
| HeadacheNervous system disorders | 2/50 | 4/51 | 20/181 |
| DizzinessNervous system disorders | 2/50 | 1/51 | 15/181 |
| FatigueGeneral disorders | 0/50 | 1/51 | 10/181 |
| Age, Continuous(years) | Not Randomized | Droxidopa | Placebo | Total |
|---|---|---|---|---|
| Mean | 69.5 ± 9.74 | 63.1 ± 13.76 | 66.6 ± 11.25 | 66.9 ± 11.62 |
| Sex: Female, Male(Participants) | Not Randomized | Droxidopa | Placebo | Total |
|---|---|---|---|---|
| Female | 35 | 20 | 19 | 74 |
| Male | 45 | 30 | 32 | 107 |
| Race (NIH/OMB)(Participants) | Not Randomized | Droxidopa | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 80 | 49 | 49 | 178 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Not Randomized | Droxidopa | Placebo | Total |
|---|---|---|---|---|
| United States | 53 | 25 | 32 | 110 |
| Canada | 8 | 9 | 2 | 19 |
| United Kingdom | 5 | 3 | 2 | 10 |
| Poland | 5 | 10 | 8 | 23 |
| Australia | 8 | 2 | 6 | 16 |
| New Zealand | 1 | 1 | 1 | 3 |
| Primary Clinical Diagnosis(participants) | Not Randomized | Droxidopa | Placebo | Total |
|---|---|---|---|---|
| Parkinson's Disease | 38 | 21 | 23 | 82 |
| Multiple System Atrophy | 21 | 17 | 13 | 51 |
| Pure Autonomic Failure | 18 | 8 | 10 | 36 |
| Dopamine Beta-Hydroxylase Deficiency | 0 | 0 | 1 | 1 |
| Non-Diabetic Autonomic Neuropathy | 2 | 2 | 3 | 7 |
| Other | 1 | 2 | 1 | 4 |
The record gives a start of Jan 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 4 years 9 months after primary completion. A results delay was requested in Jan 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Droxidopa